Clinical Trial: Adrenal Scans With Radioiodine-Labeled Norcholesterol (NP-59)

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Adrenal Scans With Radioiodine-Labeled Norcholesterol (NP-59)

Brief Summary: The purpose of this study is to find out if your adrenal glands are normal or abnormal. This can be determined by whether or not your adrenal gland concentrates more of a labeled building block of adrenal hormone, norcholesterol. This labeled material had been used as an investigative diagnostic tool for imaging adrenal glands for many years with success in our hands. This is a diagnostic procedure. CT, MRI and Ultrasound can determine the size and presence or absence of tumor but cannot assess the function of the adrenal glands. To determine hormone concentrations from blood samples would involve more invasive catherization.

Detailed Summary: To investigate the feasibility of using NP-59 to localize adrenal tumors and assess their functions under the influence of pharmacological manipulations.
Sponsor: Memorial Sloan Kettering Cancer Center

Current Primary Outcome: To investigate the feasibility of using NP-59 to localize adrenal tumors and assess their functions under the influence of pharmacological manipulations. [ Time Frame: 1 year ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Memorial Sloan Kettering Cancer Center

Dates:
Date Received: December 26, 2007
Date Started: July 1977
Date Completion:
Last Updated: December 23, 2015
Last Verified: December 2015